Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

Exclusion Criteria

• •Patient received 2 or more alkylating agents, such as VBMCP (a combination of Vincristine, BCNU (Bis-Chloronitrosourea), Melphalan, Cyclophosphamide, and Prednisone)
• •Patient received a total dose of ≧200 mg of prior melphalan
• •A co-morbid condition which, in the view of the investigators, renders the patient at high risk from treatment complications
• •Patient has failed previous collections or collection attempts
• •A residual acute medical condition resulting from prior chemotherapy
• •Brain metastases or carcinomatous meningitis
• •Acute infection
• •Fever (temperature \>38 °C / 100.4 °F)
• •Hypercalcemia (\>1mg/dl above ULN)
• •Positive pregnancy test in female patients
• •Lactating females
• •Patients of childbearing potential unwilling to implement adequate birth control
• •Patients whose actual body weight exceeds 175% of their ideal body weight
• •History of ventricular arrhythmias
• •Patient received thalidomide within 10 days prior to receiving the first dose of plerixafor
• •Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol or who are currently enrolled in another experimental protocol during the mobilization phase